NeuroVax for Multiple Sclerosis

Phase-Based Progress Estimates
CRO, San Diego, CAMultiple Sclerosis+1 MoreNeuroVax - Biological
18 - 50
All Sexes
What conditions do you have?

Study Summary

This trial is studying a vaccine called NeuroVax to see if it is better than a placebo at treating people with secondary progressive multiple sclerosis.

Eligible Conditions
  • Multiple Sclerosis
  • Secondary Progressive Multiple Sclerosis

Treatment Effectiveness

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 48 Weeks

48 Weeks
Analyses of clinical relapses
Immunologic evaluations
Measures of neurologic disability EDSS score
Safety Evaluation
Secondary MRI measurements objectives include additional MRI measurements, analyses of clinical relapses, measures of neurologic disability, immunologic evaluations, and safety.
up to 48 weeks
The primary objective is to compare between treatment groups the cumulative number of new gadolinium enhancing (Gd+) lesions on brain MRI at up to 48 weeks in subjects with secondary progressive MS

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

1 of 2
IFA Placebo
1 of 2

Experimental Treatment

Non-Treatment Group

200 Total Participants · 2 Treatment Groups

Primary Treatment: NeuroVax · Has Placebo Group · Phase 2 & 3

Experimental Group · 1 Intervention: NeuroVax · Intervention Types: Biological
IFA Placebo
PlaceboComparator Group · 1 Intervention: IFA Placebo · Intervention Types: Biological

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 48 weeks

Who is running the clinical trial?

Immune Response BioPharma, Inc.Lead Sponsor
4 Previous Clinical Trials
688 Total Patients Enrolled
2 Trials studying Multiple Sclerosis
162 Patients Enrolled for Multiple Sclerosis
1 Previous Clinical Trials
150 Total Patients Enrolled
1 Trials studying Multiple Sclerosis
150 Patients Enrolled for Multiple Sclerosis
Richard M Bartholomew, Ph.DStudy DirectorImmune Response BioPharma, Inc.
2 Previous Clinical Trials
162 Total Patients Enrolled
2 Trials studying Multiple Sclerosis
162 Patients Enrolled for Multiple Sclerosis

Eligibility Criteria

Age 18 - 50 · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

What other medical tests have used NeuroVax as a primary treatment?

"There are two ongoing clinical trials evaluating the efficacy of NeuroVax. One is in Phase 3 and both are based out of California, with one being in San Diego and the other having an unknown location." - Anonymous Online Contributor

Unverified Answer

Who meets the requirements to participate in this experiment?

"This study is recruiting 200 individuals with multiple sclerosis that are between 18-50 years old. Most importantly, potential participants must meet the following conditions: Be diagnosed with MS using the revised McDonald criteria from 2005, have a secondary progressive course of the disease, an EDSS score of 3.5 or higher (Appendix B), have had two documented clinical relapses in MS in the past 24 months OR one relapse in the 12 months prior to screening , creatinine level 1 . 5x above normal, and hemoglobin levels within normal range." - Anonymous Online Contributor

Unverified Answer

Are we still looking for volunteers for this experiment?

"The clinical trial, which was posted on March 9th 2020 and last updated on the same day, is presently looking for patients according to information available on" - Anonymous Online Contributor

Unverified Answer

How many people are being treated as part of this clinical research?

"Yes, the trial is recruiting patients at this time. The original posting date was March 9th, 2020 and there have been no updates since then. They are looking for 200 participants from a single site." - Anonymous Online Contributor

Unverified Answer

Have other medical studies like this been conducted before?

"NeuroVax was first studied in 2020 by Immune Response BioPharma, Inc. The Phase 2 & 3 drug approval followed the initial study of 200 patients. As of now, there are two active clinical trials involving NeuroVax being conducted across one city and one nation." - Anonymous Online Contributor

Unverified Answer

Are people of all ages welcome in this clinical trial?

"This clinical trial has age restrictions of 18-50, as outlined in the inclusion criteria." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.